Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment. Berlin Cures Bahrain Iran Iraq Jordan Kuwait Lebanon Oman Palestine Qatar Saudi Arabia Syria United Arab Emirates Yemen Algeria Egypt Libya Morocco Sudan Tunisia Western Sahara Germany British Columbia Austria

Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed.Berlin Cures innovative platform develops novel aptamer-based drugs to neutralize pathogenic functional autoantibodies, targeting diseases.View original content:https://www.prnewswire.co.uk/news-releases/berlin-cures-bc-007-targets-long-covid-solid-phase-ii-trial-progress-with-over-50-patient-recruitment-302078490.html